Why Is BIAFW Stock Surging in Premarket Trading Today?
-
最新报道：bioAffinity Technologies (NASDAQ: BIAFW) surged over 52% in premarket trading to $0.1164 after releasing three case studies demonstrating the clinical effectiveness of its CyPath Lung diagnostic test. The studies showed how the noninvasive test helped detect Stage 1A lung cancer in one patient, avoided unnecessary biopsies in another, and guided treatment decisions in a high-risk COPD patient. The company's technology, which shows 92% sensitivity and 87% specificity in clinical studies, addresses critical needs in early lung cancer detection while the company continues its commercial rollout with Q2 2025 revenue of $1.27 million.
下一篇
Is MrBeast Really Loading up on ASTER, 'New BNB' That Surged 8,000%?
- Aster, a decentralized perpetual exchange incubated by former Binance Labs YZi Labs, surge...
24小时热点
热点专题
418154